Acyclovir treatment for HSV in febrile hospitalized children at Jinan Children's Hospital

This retrospective cohort study examined 100 febrile hospitalized children at Jinan Children's Hospital to evaluate the management of herpes simplex virus infection. The population consisted of pediatric patients presenting with fever, and the exposure involved HSV detection methods, specifically serum HSV-IgM antibody assays and/or HSV-DNA detection, combined with treatment regimens that included individualized acyclovir courses. No specific comparator group was defined in the provided data.

The primary outcomes assessed were clinical features, laboratory findings, and treatment outcomes. Secondary outcomes included the status of co-detected pathogens and prognostic outcomes. The study did not report specific numerical results for these outcomes, nor did it provide data on the relative reduction of symptoms or specific survival rates. Consequently, the magnitude of the treatment effect remains undefined in this summary.

Safety and tolerability data were not reported for this cohort. There were no reported adverse events, serious adverse events, discontinuations, or specific tolerability metrics. The study design is observational, which limits the ability to infer causality between the intervention and the observed outcomes. Additionally, the follow-up duration was not reported, preventing assessment of long-term outcomes.

Key limitations include the absence of reported numerical results for primary and secondary outcomes, the lack of a defined comparator, and the retrospective nature of the data collection. Funding or conflicts of interest were not reported. While the study aims to provide an evidence-based basis for early clinical screening, differential diagnosis, and targeted intervention of HSV in pediatric febrile cases, the lack of quantitative efficacy data and safety reporting restricts its immediate utility for specific clinical decision-making without further validation.